Mesothelioma Cancer Resources Blog

Source: Cytopia Limited Cytopia Limited, a privately-held biotechnology firm from Australia, has recently announced that its anti-cancer drug CYT997 has begun a Phase II clinical trial for the treatment of relapsed or refractory multiple myeloma. Cytopia also announced that along with an upcoming Phase II clinical trial for the treatment of glioblastoma multiforme, they are …

Source: Industrial Health 2007, 45, 787-792 As awareness of the hazards of asbestos exposure became more common during the last few decades, many developed nations implemented statutory protocols strictly regulating the manner in which asbestos could be commercially used. Some of these nations even moved past regulation and enacted outright bans on the use of …

p>Clinical Trial Phase: Phase 2 Start Date: June 2005 Overall Status: Recruiting Estimated Enrollment: 53 Rationale Condition Keyword(s): Mesothelioma Interventions: Drug: pemetrexed Drug: cisplatin   Phase II trial of Neoadjuvant Chemotherapy with Pemetrexed plus Cisplatin followed by Surgery and Radiotherapy in patients with Malignant Pleural Mesothelioma stage I-III. The event-free survival is the primary endpoint …

Rationale After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is currently used safely as in intra-operative treatment for malignant pleural mesothelioma. This study is aimed to determine if the addition of gemcitabine as a second …

Last Updated: January 21, 2008 Clinical Trial Phase: Phase 2 Start Date: December 2006 Overall Status: Recruiting Estimated Enrollment: 30 Condition Keyword(s): Non-Small Cell Lung Cancer Mesothelioma Lung Neoplasms Intervention(s): Drug: pemetrexed Rationale This study will test the effects of pemetrexed on mesothelioma and lung cancer patients with fluid around their lungs or abdomen. Study …

Exploiting the immunostimulatory capacities of dendritic cells holds great promise for cancer immunotherapy. A mouse model for malignant mesothelioma allowed us to prove that autologous dendritic cells presenting tumor antigens were very effective by (partly) inhibiting tumor growth. This study will test the feasibility and safety of a clinical trial using autologous DC as a …

The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma… Date First Received: January 3, 2006 Last Updated: September 8, 2006 Verified by: Rigshospitalet, Denmark, September 2006 Clinical Trial Phase: Phase 2 Start Date: September 2004 Overall Status: Recruiting Estimated …

A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and …

Date First Received: February 26, 2008 Last Updated: March 5, 2008 Verified by: Columbia University, February 2008 Clinical Trial Phase: Phase 1 Start Date: October 2007 Overall Status: Recruiting Estimated Enrollment: 24 Condition Keyword(s): Soft Tissue Sarcoma; Mesothelioma Intervention(s): Drug: Azacitidine In Combination With Temozolomide Rationale The purpose of this study is to determine safety and …

Last Updated: August 28, 2007 Rationale Official Title: “Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-Line Therapy in Patients With Malignant Pleural Mesothelioma” Condition Keyword(s): Mesothelioma Intervention(s): Drug: bevacizumab Drug: pemetrexed Drug: carboplatin Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Detailed …